Skip to main content
Premium Trial:

Request an Annual Quote

Pressure Biosciences Raises $730K in Fourth Closing of Private Placement

NEW YORK (GenomeWeb) – Pressure Biosciences said today that is has completed the fourth closing of its $5 million private placement.

With the closing the company raised an additional $730,000, bring the total amount raised in the offering to nearly $4.8 million. It will issue senior secured debentures with a fixed conversion price of $.28 per restricted common share and common stock purchase warrants exercisable into a total of 1,303,571 shares of restricted stock at an exercise price of $.40 per share.

Pressure Biosciences used the proceeds, which amounted to $675,000 after fees, to eliminate all of its variable rate convertible debt.

The company said it plans one or more additional closings in the future.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.